These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27546346)

  • 1. Validation of two commercial real-time PCR assays for rapid screening of the HLA-B*57:01 allele in the HIV clinical laboratory.
    Avidor B; Girshengorn S; Giladi L; Israel S; Katz R; Turner D
    J Virol Methods; 2016 Nov; 237():18-24. PubMed ID: 27546346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Analysis of Real-Time Polymerase Chain Reaction Methods to Typing HLA-B*57:01 in HIV-1-Positive Patients.
    Falasca F; Dello Russo C; Mora B; Pirazzoli A; Fantauzzi A; Navarra P; Pizzuti A; De Vito C; Antonelli G; Turriziani O
    AIDS Res Hum Retroviruses; 2016 Jul; 32(7):654-7. PubMed ID: 26750774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers among HIV-Infected Patients in Serbia.
    Siljic M; Salemovic D; Cirkovic V; Pesic-Pavlovic I; Todorovic M; Ranin J; Dragovic G; Jevtovic D; Stanojevic M
    Intervirology; 2017; 60(1-2):43-47. PubMed ID: 28772259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing.
    Meini G; Dello Russo C; Allice T; Barresi R; D'Arrigo R; Falasca F; Lipsi MR; Paolucci S; Zanussi S; Antonetti R; Baldanti F; Basaglia G; Bruzzone B; Polilli E; Ghisetti V; Pucillo LP; Turriziani O; Pirazzoli A; Navarra P; Zazzi M
    J Clin Virol; 2016 May; 78():1-3. PubMed ID: 26946153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA- B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity.
    Manglani MV; Gabhale YR; Lala MM; Sekhar R; More D
    Indian Pediatr; 2018 Feb; 55(2):140-141. PubMed ID: 29242412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data.
    Dello Russo C; Lisi L; Fabbiani M; Gagliardi D; Fanti I; Di Giambenedetto S; Cauda R; Navarra P
    Pharmacogenomics; 2014 Feb; 15(3):319-27. PubMed ID: 24533711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCP5 rs2395029 is a rapid and inexpensive alternative to HLA-B*57:01 genotyping to predict abacavir hypersensitivity reaction in Spain.
    Zubiaur P; Saiz-Rodríguez M; Villapalos-García G; Navares-Gómez M; Koller D; Abad-Santos F
    Pharmacogenet Genomics; 2021 Apr; 31(3):53-59. PubMed ID: 33044391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.
    De Spiegelaere W; Philippé J; Vervisch K; Verhofstede C; Malatinkova E; Kiselinova M; Trypsteen W; Bonczkowski P; Vogelaers D; Callens S; Ruelle J; Kabeya K; De Wit S; Van Acker P; Van Sandt V; Emonds MP; Coucke P; Sermijn E; Vandekerckhove L
    PLoS One; 2015; 10(4):e0123525. PubMed ID: 25874872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].
    Pérez Prior N; Rocher Milla A; Soler Company E; Flores Cid J; Sarria Chust B
    Farm Hosp; 2009; 33(3):155-60. PubMed ID: 19712599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR.
    Dello Russo C; Lisi L; Lofaro A; Di Giambenedetto S; Federico B; Madeddu G; Salerno M; Mura MS; Pirazzoli A; de Luca A; Cauda R; Navarra P
    Pharmacogenomics; 2011 Apr; 12(4):567-76. PubMed ID: 21521028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.
    Moragas M; Belloso WH; Baquedano MS; Gutierrez MI; Bissio E; Larriba JM; Fay F; Aulicino P; Gurevich JM; Yaunguzian MF; Maldonado AC; Falistocco C; Sen L; Mangano A
    Tissue Antigens; 2015 Jul; 86(1):28-31. PubMed ID: 25922880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful translation of pharmacogenetics into the clinic: the abacavir example.
    Phillips E; Mallal S
    Mol Diagn Ther; 2009; 13(1):1-9. PubMed ID: 19351209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-B*5701 frequency in Chilean HIV-infected patients and in general population.
    Poggi H; Vera A; Lagos M; Solari S; Rodríguez P L; Pérez CM
    Braz J Infect Dis; 2010; 14(5):510-2. PubMed ID: 21221482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometry analysis with a new FITC-conjugated monoclonal antibody-3E12 for HLA-B*57:01 rapid screening in prevention of abacavir hypersensitivity in HIV-1-infected patients.
    Rodríguez-Sáinz C; Valor L; Hernández DC; Gil J; Carbone J; Pascual-Bernaldez M; Rodríguez-Alcántara F; Martínez I; Vicario JL; Mallal S; Fernández-Cruz E
    HIV Clin Trials; 2013; 14(4):160-4. PubMed ID: 23924588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
    Munderi P; Snowden WB; Walker AS; Kityo C; Mosteller M; Kabuye G; Thoofer NK; Ssali F; Gilks CF; Hughes AR;
    Trop Med Int Health; 2011 Feb; 16(2):200-4. PubMed ID: 21091860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
    Berka N; Gill JM; Liacini A; O'Bryan T; Khan FM
    Hum Immunol; 2012 Feb; 73(2):164-7. PubMed ID: 22197535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV.
    Quiros-Roldan E; Gardini G; Properzi M; Ferraresi A; Carella G; Marchi A; Malagoli A; Focà E; Castelli F
    Pharmacogenet Genomics; 2020 Oct; 30(8):167-174. PubMed ID: 32453265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701.
    Rodríguez-Nóvoa S; Cuenca L; Morello J; Córdoba M; Blanco F; Jiménez-Nácher I; Soriano V
    J Antimicrob Chemother; 2010 Aug; 65(8):1567-9. PubMed ID: 20534626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil.
    Crovella S; Biller L; Santos S; Salustiano A; Brandao L; Guimaraes R; Segat L; Lima Filho JL; Arraes LC
    Clinics (Sao Paulo); 2011; 66(8):1485-8. PubMed ID: 21915505
    [No Abstract]   [Full Text] [Related]  

  • 20. HLA-B*5701 screening for hypersensitivity to abacavir.
    Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
    N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.